Rhythm Pharmaceuticals, Inc. RYTM Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s payments to acquire short-term investments?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported payments to acquire short-term investments of $42.2M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s payments to acquire short-term investments changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s payments to acquire short-term investments increased by 25.9% year-over-year, from $33.52M to $42.2M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s payments to acquire short-term investments?
- Over 3 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s payments to acquire short-term investments has grown at a -12.8% compound annual growth rate (CAGR), from $524.97M to $348.67M.